International Journal of Drug Development and Research

  • ISSN: 0975-9344
  • Journal h-index: 51
  • Journal CiteScore: 46.50
  • Journal Impact Factor: 26.99
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Euro Pub
  • Google Scholar
  • J-Gate
  • Secret Search Engine Labs
  • ResearchGate
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page

Regulation and Control of the Importation, Exportation, Manufacture, Advertisement, Distribution, Sale and the Use of Medicines, Cosmetics, Medical Devices and Chemicals

Joint Event on 23rd International Conference and Exhibition on PHARMACEUTICAL FORMULATIONS & 13th International Conference and Exhibition on PHARMACOVIGILANCE & DRUG SAFETY
July 27-28, 2020 | Webinar

Abdeen Omer


Posters & Accepted Abstracts: Int J Drug Dev & Res


The strategy of price liberalisation and privatisation had been implemented in Sudan over the last decade, and has had a positive result on government deficit. The investment law approved recently has good statements and rules on the above strategy in particular to pharmacy regulations. Under the pressure of the new privatisation policy, the government introduced radical changes in the pharmacy regulations. To improve the effectiveness of the public pharmacy, resources should be switched towards areas of need, reducing inequalities and promoting better health conditions. Medicines are financed either through cost sharing or full private. The role of the private services is significant. A review of reform of financing medicines in Sudan is given in this article. Also, it highlights the current drug supply system in the public sector, which is currently responsibility of the Central Medical Supplies Public Corporation (CMS). In Sudan, the researchers did not identify any rigorous evaluations or quantitative studies about the impact of drug regulations on the quality of medicines and how to protect public health against counterfeit or low quality medicines, although it is practically possible. However, the regulations must be continually evaluated to ensure the public health is protected against by marketing high quality medicines rather than commercial interests, and the drug companies are held accountable for their conducts.
Recent Publications:
1. Abdeen M. Omer (2013). Chapter 5: Regulatory privatisation, social welfare services and its alternatives, In: Advances in Medicines and Biology, Vol.72, Editor: Leon V. Berhardt, 2013 NOVA Science Publishers, Inc., pp. 69-86, New York, USA, 2013.
2. K. Ravi Shankar, N. Sita Ratna Kumari and G.V.N. Kiranmayi (2014). In vitro Study of Antioxidant and Antimalarial Activities of New Chromeno-Pyrano-Chromene Derivative, American Journal of Phytomedicine and Clinical Therapeutics, AJPCT (2)9: 1169-1176.
3. V.Velpandian, S. Elangovan, L. Naansi Agnes and M. Mohamed Musthafa (2014). Clinical Evaluation of Justicia tranquebariensis L. In the Management of Bronchial Asthma, American Journal of Phytomedicine and Clinical Therapeutics, AJPCT (2)9: 1103-1111. 2014.
4. Abdeen M. Omer (2011). The impact of the pharmaceutical regulations on the quality of medicines on the Sudanese market: importers’ perspective, Prime Journals of Business Administration and Management (BAM), Vol.1, No.9, pp.295-302, Nigeria, October 2011.